| scholarly article | Q13442814 |
| P50 | author | Mihai Gheorghiade | Q60059386 |
| Jerzy Korewicki | Q68692790 | ||
| Witold Rużyłło | Q9375823 | ||
| P2093 | author name string | Dimitrios Kremastinos | |
| Paolo Carminati | |||
| Hani N Sabbah | |||
| Gerasimos S Filippatos | |||
| Cezar Macarie | |||
| John E A Blair | |||
| Giovanni Valentini | |||
| HORIZON-HF Investigators | |||
| Maria Bianchetti | |||
| Maurizio Ceracchi | |||
| Serban I Bubenek-Turconi | |||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| heart failure | Q181754 | ||
| echocardiography | Q216933 | ||
| hemodynamics | Q1642137 | ||
| hospitalization | Q3140971 | ||
| P304 | page(s) | 2276-2285 | |
| P577 | publication date | 2008-04-09 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure | |
| P478 | volume | 51 |
| Q37291720 | Acute Heart Failure Treatment |
| Q42972084 | Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events? |
| Q24645066 | Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond |
| Q37358922 | Beta-adrenergic stimulation and myocardial function in the failing heart |
| Q38017919 | Calcium handling in human heart failure--abnormalities and target for therapy |
| Q37851240 | Cardiac inotropes: current agents and future directions |
| Q37913110 | Cardio-renal syndrome: an entity cardiologists and nephrologists should be dealing with collegially |
| Q38074093 | Causes and treatment of oedema in patients with heart failure |
| Q37941602 | Clinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure, 12 May 2009. |
| Q37929868 | Contemporary management and research directions in advanced heart failure: where are we going? |
| Q38009708 | Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure |
| Q37817025 | Current treatment in acute and chronic cardio-renal syndrome |
| Q43711626 | Do inotropes really have a future? |
| Q57293272 | Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials |
| Q39837671 | Evolving Approaches to the Management of Heart Failure with Preserved Ejection Fraction in Patients with Coronary Artery Disease |
| Q37269322 | Functional characterization and anti-cancer action of the clinical phase II cardiac Na+/K+ ATPase inhibitor istaroxime: in vitro and in vivo properties and cross talk with the membrane androgen receptor. |
| Q42907027 | Inotropic Therapy for End-Stage Heart Failure Patients |
| Q94566824 | Istaroxime in acute heart failure: the holy grail is at HORIZON? |
| Q42008108 | Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition. |
| Q37399996 | Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? |
| Q41472411 | Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium |
| Q38734731 | Long-term intravenous inotropes in low-output terminal heart failure? |
| Q37427227 | Major recent trials in cardiovascular diseases |
| Q37920401 | Medical therapy for chronic heart failure |
| Q37403197 | Newer treatments for decompensated heart failure: focus on levosimendan |
| Q38224809 | Nitroxyl (HNO) for treatment of acute heart failure |
| Q33946688 | Nitroxyl (HNO): A novel approach for the acute treatment of heart failure |
| Q38073647 | Novel pharmacologic therapies in development for acute decompensated heart failure |
| Q41856322 | Novel strategies for the treatment of heart failure |
| Q37893956 | Novel therapeutic targets for the treatment of heart failure. |
| Q37312758 | Pathological ventricular remodeling: therapies: part 2 of 2. |
| Q47907201 | Pharmacologic Management for Heart Failure and Emerging Therapies |
| Q89903377 | Pharmacological interventions for heart failure in people with chronic kidney disease |
| Q36906123 | Phase II trials in heart failure: the role of cardiovascular imaging |
| Q88711524 | Pulmonary Oedema-Therapeutic Targets |
| Q83482179 | Role and mechanism of subcellular Ca2+ distribution in the action of two inotropic agents with different toxicity |
| Q33816527 | Role of inotropic agents in the treatment of heart failure. |
| Q37418216 | SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope. |
| Q42014726 | SERCA2a stimulation by istaroxime: a novel mechanism of action with translational implications |
| Q38868193 | Similar hemodynamic decongestion with vasodilators and inotropes: systematic review, meta-analysis, and meta-regression of 35 studies on acute heart failure |
| Q35763705 | Targeting cardiomyocyte Ca2+ homeostasis in heart failure |
| Q37703984 | The current and future management of acute heart failure syndromes |
| Q38366647 | The regulation of sarco(endo)plasmic reticulum calcium-ATPases (SERCA). |
| Q92895515 | Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial |
| Q39258163 | Update on the Management of Acute Decompensated Heart Failure |
| Q37858515 | Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents |
| Q92588956 | Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials |
| Q83250047 | [Advances in heart failure] |
| Q83320623 | [Heart failure and heart transplant] |
Search more.